A system for calculating cardiac output (CO) of a patient undergoing veno-arterial extracorporeal oxygenation includes measuring first oxygenated blood flow rate by a pump in the extracorporeal blood oxygenation circuit as introduced into an arterial portion of the patient circulation system and a corresponding arterial oxygen saturation, then changing the pump flow rate, such as decreasing, to produce a corresponding change in arterial oxygen saturation (wherein such change is outside of normal operating variances, operating errors or drift), which change in the arterial oxygen saturation is measured. From the first flow rate and the second flow rate along with the corresponding measured arterial oxygen saturation, the CO of the patient can be calculated, without reliance upon a measure of venous oxygen saturation. Alternatively, the CO of the patient can be calculated, without reliance upon a change in flow rate by changing a gas exchange with the blood in the extracorporeal blood oxygenation circuit to impart corresponding changes in a blood parameter in the arterial portion of the patient circulation system and the blood delivered from the extracorporeal blood oxygenation circuit.

In one embodiment, a monitoring system includes a monitoring device configured to removably attach to a tracheotomy tube, the monitoring device including a skin sensor configured to detect contact with skin of a patient's neck.

A respiration device (1) supports cardio-pulmonary resuscitation (CPR) and a method for operating a respiration device (1) supports cardio-pulmonary resuscitation (CPR). The respiration device (1) has a control and regulation unit (7) in order to actuate an expiratory metering unit (3), and an inspiratory metering unit (2) such that, in a first phase, a current value of pressure is increased relative to a first pre-defined value (16) and such that, in a second phase, the current value of the pressure is reduced relative to the first pre-defined value (16).

A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, which can include information relating to a potential respiratory equilibrium, and a duration of safe apnoea is determined from the obtained information.

A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, which can include information relating to a potential respiratory equilibrium, and a duration of safe apnoea is determined from the obtained information.

The present disclosure relates to a method for continuous and noninvasive estimation of mixed venous blood saturation [SvO2] in a mechanically ventilated subject (3). The method comprises the steps of measuring (S1; S10) an expiratory carbon dioxide [CO2] content in expiration gas exhaled by the subject, measuring (S2; S20) an expiratory flow or volume of expiration gas exhaled by the subject, estimating (S3; S30) a cardiac output [CO] or an effective pulmonary blood flow [EPBF] of the subject from the measured expiratory CO2 content and the measured expiratory flow or volume using a capnodynamic Fick method, and estimating (S4; S40) SvO2 based on the estimated CO or the EPBF of the subject.

An information display and control system that enables a fast and easy understanding and management of the status of the patient's dialysis is disclosed. Also disclosed is an information display and control system that enables a fast and easy understanding and management of the status of the patient's cardiovascular and ventilation systems. The system can control management of a patient's dialysis, as well as administration and management of a patient's medication and fluids. The display is organized by goals related to management of patient's dialysis machine, blood flow, dialyzer flow, and patient's body weight. The display is also organized by goals related to management of patient's cardiovascular system, ventilation system, and medications and fluids administration and management. Such goals include urea reduction rate, urea reduction ratio, fractional urea clearance, total urea reduction, dialysis treatment duration, hemodynamics, oxygenation, CO.sub.2 removal, medication status, and fluids status.

A system and method for measuring the effectiveness of a dose from an inhaler on a user is disclosed. The inhaler includes a drug container and a dosing mechanism coupled to the drug container to aerate a dose from the drug container. The dosing mechanism provides the aerated dose to the user. A sensor interface is in communication with a physiological sensor. The physiological sensor is attached to a user to sense a physiological response to the dose. Physiological data is sent to the sensor interface. A controller is coupled to the sensor interface to collect the sensed physiological data from the user corresponding to the time that the aerated dose is delivered to the user. The effectiveness of the dose may be determined from the collected data. The dose amount or frequency may be changed or the drug may be changed based on the collected data.

A system and method for measuring the effectiveness of a dose from an inhaler on a user is disclosed. The inhaler includes a drug container and a dosing mechanism coupled to the drug container to aerate a dose from the drug container. The dosing mechanism provides the aerated dose to the user. A sensor interface is in communication with a physiological sensor. The physiological sensor is attached to a user to sense a physiological response to the dose. Physiological data is sent to the sensor interface. A controller is coupled to the sensor interface to collect the sensed physiological data from the user corresponding to the time that the aerated dose is delivered to the user. The effectiveness of the dose may be determined from the collected data. The dose amount or frequency may be changed or the drug may be changed based on the collected data.

The present invention generally relates to a process suitable for extracorporeal lung support. The process comprises contacting blood with a dialysis liquid separated by a semipermeable membrane. Oxygen is introduced into blood and/or into the dialysis liquid prior to contacting blood and dialysis liquid being separated by the semipermeable membrane. The process is versatile and allows for blood oxygenation as well as removal of at least one undesired substance occurring in the blood, selected from carbon dioxide, bicarbonate and hydrogen cations, from blood. Thereby, the present invention takes advantage of the Haldane effect in the extracorporeal contacting step. The undesired substance can be efficiently transported across a semipermeable membrane to the dialysis liquid. In contrast to extracorporeal carbon dioxide removal methods of the prior art (ECCCbR), the present invention employs a versatile dialysis liquid that allows to adjust the pH and buffering capacity of the dialysis liquid, to add fluids to the dialysis liquid and/or to the blood and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. The present invention also provides regeneration and recycling of the dialysis liquid, and thus for its repeated use. The present invention is suitable for treating human or animal subjects suffering from lung failure or lung disorders.